Lead change of a HIF-2α antagonist guided by multiparameter optimization and utilization of an Olp→πAr interaction

• Published in: Medicinal chemistry research 2023-07, Vol.32 (7), p.1510-1531
• Main Authors: Wehn, Paul M., Yang, Song, Grina, Jonas A., Rizzi, James P., Schlachter, Stephen T., Wang, Bin, Xu, Rui, Yang, Hanbiao, Du, Xinlin, Han, Guangzhou, Wang, Keshi, Czerwinski, Robert M., Ged, Emily L., Huang, Heli, Halfmann, Megan M., Maddie, Melissa A., Morton, Emily R., Olive, Sarah R., Tan, Huiling, Xie, Shanhai, Josey, John A., Wallace, Eli M.
• Format: Article
• Language: English
• Subjects: Antagonism; Antagonists; Biochemistry; Biomarkers; Biomedical and Life Sciences; Biomedicine; Bioorganic Chemistry; Electrostatic properties; Inhibitors; Inorganic Chemistry; Medicinal Chemistry; Optimization; Original Research Article; Parameter modification; Pharmacodynamics; Pharmacokinetics; Pharmacology/Toxicology; Solubility
• ISSN: 1054-2523; 1554-8120
• DOI: 10.1007/s00044-023-03088-w

Pharmacokinetic properties of our first-generation HIF-2α antagonist PT2385, including modest solubility, resulted in a high recommended phase 2 dose (RP2D) of 800 mg BID and motivated the pursuit of novel scaffolds which could improve solubility and formulation parameters with the goal of improved pharmacokinetics. Herein we disclose our successful efforts to identify such HIF-2α antagonists through an optimization strategy characterized by: (1) increasing the fraction of sp 3 hybridized carbons (Fsp 3 ), (2) replacing the aromatic portion of the indane core with pyridine heterocycles, and (3) improving a putative O lp →π* Ar interaction, an underutilized electrostatic contact in medicinal chemistry. These efforts emphasize the importance of employing multiple strategies in parameter optimization. In isolation, modifications to areas (1) and (2) improved solubility, but with the compromise of reduced potency. In area (3), understanding the importance of an O lp →π* Ar interaction, as documented through a wealth of crystal structures and retrospective calculations, proved essential in guiding SAR and identifying the trifluoromethyl group as a suitable replacement of the sulfone. Only by combining these three strategies could inhibitors with substantially improved solubility and comparable potency be discovered. Finally, the overall improvement in pharmacokinetic properties of the newly identified inhibitors is highlighted through a battery of ADME and in vivo data, including use of pharmacodynamic biomarkers indicative of HIF-2α antagonism.